MET and non-small cell lung carcinoma: The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib and tepotinib, on May 2020 and February 2021 respectively, for patients with metastatic NSCLC harboring MET exon 14 skipping alterations.